Publications

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of Individual Patient-Level Data from Daratumumab Clinical Trials

AuthID
P-017-ND6

Author(s)

Yong, K

Einsele, H

Schecter, JM

Roccia, T

Deraedt, W

Lendvai, N

Slaughter, A

Lonardi, C

Connors, K

Qi, KQ

Londhe, A

Carson, R

Kharat, A

Cost, P

Valluri, S

Mendes, J

Pacaud, L

Patel, N

Florendo, E

Dhakal, B

Document Type

Article

Year published

2025

Published

in EUROPEAN JOURNAL OF CANCER, ISSN: 0959-8049

Volume: 215

Indexing

Wos^®

Scopus^®

Pubmed^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.ejca.2024.115157

Pubmed: 39673835

Scopus: 2-s2.0-85211582731

Wos: WOS:001390131800001

Source Identifiers

ISSN: 0959-8049

Export Publication Metadata

Marked List

Add to Marked List

Info

At this moment we don't have any links to full text documens.

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of Individual Patient-Level Data from Daratumumab Clinical Trials

Useful Links

Get Help

Federated Authentication (Click on the image)

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of Individual Patient-Level Data from Daratumumab Clinical Trials

Useful Links

Get Help